Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cybin Inc. stock logo
CYBN
Cybin
$8.32
-1.7%
$7.85
$4.81
$13.88
$194.78M0.69291,101 shs436,714 shs
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
$1.15
$1.06
$0.45
$1.68
$57.22M1.57.44 million shs15.01 million shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$22.34
-1.2%
$19.01
$2.03
$14.36
$209.95M1.1150,104 shs111,114 shs
Procaps Group S.A. stock logo
PROC
Procaps Group
$0.95
-40.3%
$0.95
$0.50
$3.78
$107.18M-0.0560,066 shs658,169 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cybin Inc. stock logo
CYBN
Cybin
-1.65%+8.90%+5.32%+13.20%+2,154.74%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
0.00%0.00%0.00%0.00%0.00%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
+0.27%+6.30%+22.69%+96.69%-49.03%
Procaps Group S.A. stock logo
PROC
Procaps Group
0.00%0.00%0.00%0.00%-62.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cybin Inc. stock logo
CYBN
Cybin
3.0884 of 5 stars
3.60.00.00.03.80.81.3
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cybin Inc. stock logo
CYBN
Cybin
3.25
Buy$85.00921.63% Upside
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
0.00
N/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A
Procaps Group S.A. stock logo
PROC
Procaps Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NEOS, CYBN, NLTX, and PROC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Cybin Inc. stock logo
CYBN
Cybin
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$73.00 ➝ $70.00
5/13/2025
Cybin Inc. stock logo
CYBN
Cybin
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/A$10.83 per shareN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
$64.65M0.89N/AN/A($0.12) per share-9.58
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
Procaps Group S.A. stock logo
PROC
Procaps Group
$409.92M0.26N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cybin Inc. stock logo
CYBN
Cybin
-$57.88M-$3.88N/AN/AN/AN/A-37.58%-36.59%N/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
-$16.90M-$0.34N/AN/AN/A-38.35%N/A-28.46%N/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A
Procaps Group S.A. stock logo
PROC
Procaps Group
$42.54MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/AN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cybin Inc. stock logo
CYBN
Cybin
N/A
24.24
24.24
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/A
0.66
0.53
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Cybin Inc. stock logo
CYBN
Cybin
17.94%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
33.13%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%
Procaps Group S.A. stock logo
PROC
Procaps Group
N/A

Insider Ownership

CompanyInsider Ownership
Cybin Inc. stock logo
CYBN
Cybin
15.00%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
3.80%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
1.58%
Procaps Group S.A. stock logo
PROC
Procaps Group
19.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cybin Inc. stock logo
CYBN
Cybin
5023.02 million17.96 millionNot Optionable
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
21349.76 millionN/AOptionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data
Procaps Group S.A. stock logo
PROC
Procaps Group
4,900112.82 million90.37 millionNot Optionable

Recent News About These Companies

Procaps Group, S.A. (PROC) stock forecast and price target
PROCF Procaps Group S.A.
Procaps Group appoints new board directors
Procaps Group S.A. (PROCF)
Procaps Group Receives Delisting Notice From Nasdaq
Procaps Group Receives Additional Delinquency Letter
A Look At The Intrinsic Value Of Procaps Group S.A. (NASDAQ:PROC)
Procaps Group Secures $40 Million Convertible Note Deal

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cybin stock logo

Cybin NYSE:CYBN

$8.32 -0.14 (-1.65%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$8.36 +0.04 (+0.49%)
As of 07/18/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Neos Therapeutics stock logo

Neos Therapeutics NASDAQ:NEOS

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$22.34 -0.26 (-1.15%)
As of 07/18/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Procaps Group stock logo

Procaps Group NASDAQ:PROC

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.